Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Original Article from The New England Journal of Medicine — Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

  • 123456 Profile photo of Madelyn

    At the same time Belinda was reported and published as well. However, despite a similar design (albeit with some potentially significant differences) Tisa-Cel was not better than chemo followed by auto transplant. Was the ability to try a second salvage regimen to help get to the auto-transplant a factor? (10% of the patients transplanted had a second salvage regimen)